drugset / Trial / NCT04653246
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
NaSingle-groupOpen-labelTreatment
Summary
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
Timeline
- Start
- 2021-07-13
- Primary completion
- 2025-12-15
- Completion
- 2029-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isatuximab | Monoclonal antibody | — | Intravenous |
| Background | Bortezomib | Small molecule | — | Subcutaneous |
| Background | Dexamethasone | Small molecule | — | Intravenous |
| Background | Lenalidomide | Other / unclassified | — | Oral |